BLBo Lennernäs

Bo Lennernäs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bo Lennernäs has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Sten Nilsson

    Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

    7 shared publications
  • Per Albertsson

    Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden

    6 shared publications
  • Ulf Isacsson

    Department of Immunology, Genetics and Pathology, Section of Medical Radiation Sci-ence, Uppsala University, Uppsala, Sweden

    3 shared publications
  • Anders Ullén

    Department of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden

    2 shared publications
  • Hemming Johansson

    Department of Oncology, Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, SE-171 78 Stockholm, Sweden

    2 shared publications
  • Khairul Majumder

    Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Oncology, Karolinska University Hospital, Stockholm, Sweden

    2 shared publications

Latest Publications

  • Magnetic Resonance Compatibility of a Transponder Aimed for Radiotherapy Positioning – A Phantom Study

    by Johan Wikstrom, Ulf Isacsson, Bengt Johansson, Bo Lennernäs

    Background/Aim: Electromagnetic Positioning Systems (EMP) is a new position-ing technique in four-dimensional radiotherapy. Patients with implanted transponders may be referred for magnetic resonance imaging (MRI) making it important to establish the MR safety. Materials and Methods: Oranges were prepared with transponders and imaged on a 3T MR scanner with different sequences. Computed tomography (CT) was performed as comparison. MR artifacts were assessed. An estimation of the maximum transponder de-flection force and heating was made. Results: The mean measured displacement of transponders was 0.1 mm (range=0.03-0.3 mm). Artifacts were observed adjacent to transponders using all sequences. The deflection force on the transponder in the gantry was less than 38 mN. No heating was observed. Conclusion: The absence of any substantial movement, the weak measured deflection force and absence of observed heating speaks for the safe use of MR imaging with transponder 3T. Local artefacts makes evaluation impossible adjacent to transponders.


  • Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes

    by Bo Lennernäs, Khairul Majumder, Jan-Erik Damber, Per Albertsson, Erik Holmberg, Yvonne Brandberg, Ulf Isacsson, Gunilla Ljung, Ole Damm, Sten Nilsson

    Background. Treatment of localized prostate cancer (PC) is controversial. This is the first randomized study comparing an open surgery procedure (radical prostatectomy) with a combination of high-dose rate brachytherapy (2 × 10 Gy) and external beam radiotherapy (25 × 2 Gy) in PC patients in Sweden 1996–2001. The two randomization arms were compared regarding differences in patients-reported outcomes, such as complications and health-related quality of life (HRQoL). Material and methods. The patients had localized/locally advanced PC, clinical category T1b–T3a, N0, M0 and PSA ≤ 50 ng/ml. All underwent total androgen blockade (six months). Self-reported HRQoL and symptoms including urinary, bowel, and sexual side effects were investigated prospectively before randomization and 12 and 24 months after randomization. A total of 89 patients were randomized and completed the EORTC QLQ C-33 and EORTC PR-25 questionnaires. Results. Over the study period, there were no discernible differences in HRQoL, or complications between the two groups. Emotional functioning, however, improved statistically significantly over time, whereas Social functioning decreased, and financial difficulties increased. No statistically significant differences in group-by-time interactions were found. The survival rate was 76%. Only eight patients (9%) died of PC. Conclusion. Open radical prostatectomy and the combined high-dose rate brachytherapy with external beam radiation appeared to be comparable in the measured outcomes. It was not possible to draw any conclusion on the efficacy of the two treatments due to insufficient power of the study.


  • Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities

    by Marie Hjälm-Eriksson, Bo Lennernäs, Anders Ullén, Hemming Johansson, Jonas Hugosson, Sten Nilsson, Yvonne Brandberg

    Effects on long-term health-related quality of life (HRQoL) were evaluated in patients treated for localized prostate cancer by two standard modalities: radical retropubic prostatectomy (RP) and external beam radiotherapy combined with a high-dose-rate brachytherapy boost (HDRBT-EBRT). The HRQoL data were compared with age-adjusted normative data. Men diagnosed with localized prostate cancer and treated with curative intent in Gothenburg, Sweden, 1988-1997 were included. HRQoL was measured in October 2000 using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires, with a response rate of 82% (n=347). No differences in patient characteristics were found between the two treatment groups, except regarding tumor stage and PSA recurrence at the time of the questionnaires. In the RP group, 42% had T1 and 6% had T3-4 tumors; corresponding proportions in the HDRBT-EBRT group were 29% and 13% (p=0.01). PSA recurrence was detected in 44% of RP patients and 9% of HDRBT-EBRT patients. In most domains, mean HRQoL scores were high and similar to the scores for the age-adjusted normative sample. However, patients reported better role and physical function compared to the normal population. We also observed more sleeping disturbances but less pain among patients than in the normal population. The disease-specific questionnaires showed statistically significant higher levels of bowel and urinary problems in the irradiated group than in the RP group, and the absolute difference between the groups was small and had minor clinical significance. We conclude that overall the general quality of life was rated high by the patients irrespective of curative treatment modality and in agreement with age-adjusted normative data. Statistically significant differences in bowel and urinary symptoms were found between the two treatment groups in favor of the RP group, but the clinical significance was small.


  • Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio – possible reasons for concerns? An example of five dimensional radiotherapy

    by Bo Lennernäs, Sten Nilsson, Seymour Levitt

    It is very attractive, due to the assumed low alfa/beta ratio of prostate cancer (PC), to construct new treatment schedules for prostate cancer using only a few large fractions of radiation (hypofractionation). This will widen the therapeutic window since the ratio for PC might be lower than that of the organs at risk (OAR). PC is an extremely variable disease and often contains both highly and poorly differentiated cells. It is reasonable to assume that different cells have different patterns of radiosensitivity, i.e. alfa/beta ratios and proliferation. In this study we will simulate the effect on the outcome of the treatment with different fractionations and different ratios. Material and methods. In this simulation we use an extension of the Linear Quadratic (LQ)/Biological Effective Dose (BED) formula called the dose volume inhomogenity corrected BED (DVIC-BED). In the formula the tumour volume is divided in 50 subvolumes (step of 2%) and it is possible to calculate the relative effect of the treatment with different ratios (1.5, 4 and 6.5) in different subvolumes. Results. The simulations demonstrate that only a small portion (5–10%) of cells with a higher ratio will dramatically change the effect of the treatment. Increasing the total dose can compensate this, but this will on the other hand increase the dose to the OAR and also the risk for severe side effects. Conclusion. These simulations highlight possible reasons for concerns about the use of hypofractionation for pathologically heterogeneous tumours, such as prostate cancer, and also demonstrate the need for testing new treatment schedules using both high and low ratios.


  • Four and five dimensional radiotherapy with reference to prostate cancer – definitions, state of the art and further directions – an overview

    by Bo Lennernäs, Enrique CastellanoS, Sten Nilsson, Seymour Levitt

    Radiotherapy (RT) always requires a compromise between tumor control and normal tissue side-effects. Technical innovation in radiation therapy (RT), such as three dimensional RT, is now established. Concerning prostate cancer (PC), it is reasonable to assume that RT of PC will increase in the future. The combination of small margins, a movable target (prostate), few fractions and high doses will probably demand dynamically positioning systems and in real time. This is called four dimensional radiotherapy (4DRT). Moreover, biological factors must be included in new treatments such as hypofractionation schedules. This new era is called five dimensional radiotherapy, 5DRT. In this paper we discuss new concepts in RT in respect to PC.


  • Zoledronic acid induces caspase dependent apoptosis in renal cancer cell lines

    by Anders Ullén, Lena Lennartsson, Karl-Mikael Kälkner, Per Sandström, Bo Lennernäs, Stig Linder, Sten Nilsson

  • Open Access

    Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer.

    by Bo Lennernäs, Per Albertsson, Maliha Edgren, Sten Nilsson

    The aim of this study was to evaluate and estimate the impact on the biological effective dose (BED) of irradiation delivered to a tumour during high dose rate brachytherapy with a heterogeneous dose distribution in the target volume. The calculation of BED in combination with the critical-voxel model and the LQ (linear quadratic) model was used to evaluate the effect of different combinations of heterogeneous dose distribution. The model is called the dose volume inhomogeneity corrected BED (DVIC-BED). Different random and non-random combinations of radiobiological parameters were used to test the model. A simulated clinical treatment of two 10 Gy fractions of brachytherapy was used. In the simulations 0-100% of the target volume was simulated to receive only 80% of the total dose. Different alpha/beta ratios as well as a different alpha value were used. A drastic effect on the outcome was observed especially when the ratio was low and the alpha value was high. The clinical effect is amplified when the tumour is considered to have a step dose respond curve. A 5 Gy decrease in dose corresponds to a reduction in clinical or chemical control < or =10-25% in the interval 65-85 Gy. Random production of different values has basically the same effect as above. The result stresses the importance to have control of the dose and the target volume during brachytherapy of prostate cancer. This is even more important when monotherapy with high dose rate brachytherapy is used and with a low alpha/beta ratio. The advantage of using this formula is that it is based on the LQ/BED formula and that different treatments with different fractions and treatments can be summated independently of the homogeneity of the dose distribution.


  • Open Access

    High dose-rate brachytherapy of prostate cancer utilising Iridium-192 after-loading technique: Technical and methodological aspects

    by M. Edgren, A. M. Ekelund, P. Albertsson, L. M. Lundberg, A. Ullen, S. Levitt, S. Nilsson, B. Lennernäs

    The aim of this study was to focus on certain characteristic problems associated with Iridium-192 high dose-rate brachytherapy (Ir-192 HDR-BT) in combination with external beam radiation therapy (EBRT) in the treatment of patients with localised prostate cancer. Over a period of 16 years, >2,000 patients with prostate cancer have been treated in Sweden with a combination of two fractions of 10 Gy Ir-192 HDR-BT and 50 Gy of fractionated EBRT. Although this treatment is usually well tolerated, there are biological and technical factors to be considered before and during the treatment of the patient to avoid side effects or under-treatment of the target volume. Some of the problems facing the doctors are transducer stability, needle deviation, target definition, target motion, pubic arch interference, concomitant diseases and tolerance doses for different organs at risk. These problems are discussed and possible solutions are presented in this study.


  • The effectiveness of artificial neural networks in evaluating treatment plans for patients requiring external beam radiotherapy.

    by Bo Lennernäs, Dan Sandberg, Per Albertsson, Åke Silén, Ulf Isacsson

    This study was designed to determine the ability of a neural network to use data summarized in artificial generated dose volume histograms (DVH) for the rectum to evaluate and compare different patient treatment plans for the treatment of localized prostate cancer. One radiotherapist evaluated 250 artificially generated DVHs representing the distribution of a dose of ration throughout the rectum during external radiotherapy for patients with prostatic adenocarcinoma (PAC). The data were also analyzed using the Lyman NTCP-model for assessing complication probabilities. A neural network consisting of 10 input nodes and one output node was trained to categorize the plans according to the radiotherapist's score. The volume in each isodose was used as input, and the risk for a severe complication was presented as output. The classifications made by the neural network matched those determined by the radiotherapist and the NTCP-model. All three techniques showed a high correlation between each other. Artificially generated dose volume histograms (DVH) for the rectum can be used for training a neural network for scoring rectal DVHs in treatment plans for localized prostate cancer.